Becton, Dickinson and Company
General ticker "BDX" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $37.8B (TTM average)
Becton, Dickinson and Company follows the US Stock Market performance with the rate: 33.1%.
Estimated limits based on current volatility of 1.0%: low 144.58$, high 147.54$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-03-10, amount 1.05$ (Y2.88%)
- Total employees count: 72000 (-2.7%) as of 2025
- Top business risk factors: Geopolitical risks, Supply chain disruptions, Regulatory and compliance, Market competition, Cybersecurity threats
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [124.43$, 182.43$]
- 2026-09-30 to 2027-09-30 estimated range: [133.27$, 192.36$]
Financial Metrics affecting the BDX estimates:
- Negative: with PPE of 10.1 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 12.03
- Positive: 6.59 < Operating cash flow per share per price, % of 8.19
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 2.94
- Negative: Industry operating profit margin (median), % of -5.26 <= 2.88
- Positive: -4.41 < Investing cash flow per share per price, % of -1.95
- Positive: 42.59 < Shareholder equity ratio, % of 45.89 <= 64.29
Short-term BDX quotes
Long-term BDX plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $19,582.00MM | $19,956.00MM | $21,444.00MM |
| Operating Expenses | $17,471.00MM | $17,559.00MM | $18,865.00MM |
| Operating Income | $2,111.00MM | $2,397.00MM | $2,579.00MM |
| Non-Operating Income | $-449.00MM | $-392.00MM | $-698.00MM |
| Interest Expense | $452.00MM | $528.00MM | $613.00MM |
| R&D Expense | $1,237.00MM | $1,190.00MM | $1,265.00MM |
| Income(Loss) | $1,662.00MM | $2,005.00MM | $1,881.00MM |
| Taxes | $132.00MM | $300.00MM | $203.00MM |
| Other Income(Loss) | $-46.00MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $1,438.00MM | $1,705.00MM | $1,678.00MM |
| Stockholders Equity | $25,797.00MM | $25,889.00MM | $25,390.00MM |
| Inventory | $3,273.00MM | $3,843.00MM | $3,894.00MM |
| Assets | $52,780.00MM | $57,286.00MM | $55,325.00MM |
| Operating Cash Flow | $2,990.00MM | $3,798.00MM | $3,430.00MM |
| Capital expenditure | $874.00MM | $725.00MM | $760.00MM |
| Investing Cash Flow | $-716.00MM | $-5,514.00MM | $-818.00MM |
| Financing Cash Flow | $-1,956.00MM | $2,087.00MM | $-3,617.00MM |
| Earnings Per Share** | $5.02 | $5.88 | $5.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.